Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20024738 | 0.89 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1ALDH1A1HTT | |
| SCHEMBL2555132 | 0.88 | ALDH1A1 (0.59) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL6538501 | 0.85 | TSHR (0.61) | RAB9AALDH1A1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL29957961 | 0.84 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2NPC1ALDH1A1HTT | |
| SCHEMBL2559464 | 0.84 | TSHR (0.60) | ALDH1A1KDM4EHPGDCYP1A2CYP2D6 | |
| SCHEMBL7921002 | 0.84 | ALDH1A1 (0.55) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL4489356 | 0.83 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL2556056 | 0.83 | ALDH1A1 (0.82) | RAB9ASMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL29951074 | 0.83 | ALDH1A1 (0.58) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL2556140 | 0.83 | ALDH1A1 (0.58) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | RAB9A 943/4885SMN1; SMN2 2439/4885NPC1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.